Fintel reports that on August 1, 2023, Morgan Stanley reiterated coverage of Pharvaris (NASDAQ:PHVS) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 6.29% Upside
As of July 6, 2023, the average one-year price target for Pharvaris is 18.07. The forecasts range from a low of 8.08 to a high of $27.30. The average price target represents an increase of 6.29% from its latest reported closing price of 17.00.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Pharvaris is 0MM. The projected annual non-GAAP EPS is -2.53.
What is the Fund Sentiment?
There are 37 funds or institutions reporting positions in Pharvaris. This is a decrease of 4 owner(s) or 9.76% in the last quarter. Average portfolio weight of all funds dedicated to PHVS is 0.91%, an increase of 86.31%. Total shares owned by institutions increased in the last three months by 0.14% to 21,921K shares.
What are Other Shareholders Doing?
Foresite Capital Management Iv holds 3,247K shares representing 7.96% ownership of the company. No change in the last quarter.
Viking Global Investors holds 3,232K shares representing 7.92% ownership of the company. No change in the last quarter.
Bain Capital Life Sciences Investors holds 3,181K shares representing 7.80% ownership of the company. No change in the last quarter.
General Atlantic holds 2,420K shares representing 5.93% ownership of the company. No change in the last quarter.
venBio Partners holds 2,279K shares representing 5.59% ownership of the company. In it's prior filing, the firm reported owning 2,297K shares, representing a decrease of 0.80%. The firm increased its portfolio allocation in PHVS by 26.99% over the last quarter.
Pharvaris Background Information
(This description is provided by the company.)
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Additional reading:
- MATERIAL UNITED STATES FEDERAL INCOME TAX AND DUTCH TAX CONSIDERATIONS
- Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
- AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G
- [SIGNATURE PAGES FOLLOW]
- Pharvaris Announces $70 Million Private Placement Financing
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
